Acetylation of CCAR2 Establishes a BET/BRD9 Acetyl Switch in Response to Combined Deacetylase and Bromodomain Inhibition.

There continues to be interest in targeting epigenetic "readers, writers, and erasers" for the treatment of cancer and other pathologies. However, a mechanistic understanding is frequently lacking for the synergy observed when combining deacetylase and bromodomain inhibitors. Here we identify cell cycle and apoptosis regulator 2 (CCAR2) as an early target for acetylation in colon cancer cells treated with sulforaphane. N-terminal acetylation of CCAR2 diminished its interactions with histone deacetylase 3 and β-catenin, interfering with Wnt coactivator functions of CCAR2, including in cells harboring genetically encoded CCAR2 acetylation. Protein domain arrays and pull-down assays identified acetyl "reader" proteins that recognized CCAR2 acetylation sites, including BRD9 and members of the bromodomain and extraterminal domain (BET) family. Treatment with the BET inhibitor JQ1 synergized with sulforaphane in colon cancer cells and suppressed tumor development effectively in a preclinical model of colorectal cancer. Studies with sulforaphane+JQ1 in combination implicated a BET/BRD9 acetyl switch and a shift in the pool of acetyl "reader" proteins in favor of BRD9-regulated target genes. SIGNIFICANCE: These results highlight the competition that exists among the "readers" of acetylated histone and nonhistone proteins and provide a mechanistic basis for potential new therapeutic avenues involving epigenetic combination treatments.

[1]  G. Johnson,et al.  Heterocyclic Analogs of Sulforaphane Trigger DNA Damage and Impede DNA Repair in Colon Cancer Cells: Interplay of HATs and HDACs , 2018, Molecular nutrition & food research.

[2]  Ling-Zhi Wang,et al.  Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma , 2018, Proceedings of the National Academy of Sciences.

[3]  Anette McLeod,et al.  Validation of histone deacetylase 3 as a therapeutic target in castration‐resistant prostate cancer , 2018, The Prostate.

[4]  B. Bernstein,et al.  Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. , 2018, Cancer cell.

[5]  S. Kummerfeld,et al.  Non-canonical reader modules of BAZ1A promote recovery from DNA damage , 2017, Nature Communications.

[6]  J. Qin,et al.  Acetylation on histone H3 lysine 9 mediates a switch from transcription initiation to elongation , 2017, The Journal of Biological Chemistry.

[7]  R. Nusse,et al.  Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities , 2017, Cell.

[8]  Y. Tai,et al.  HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications , 2017, Leukemia.

[9]  David E. Williams,et al.  A functional pseudogene, NMRAL2P, is regulated by Nrf2 and serves as a coactivator of NQO1 in sulforaphane‐treated colon cancer cells , 2017, Molecular nutrition & food research.

[10]  L. Aravind,et al.  A conserved NAD+ binding pocket that regulates protein-protein interactions during aging , 2017, Science.

[11]  Ming-Ming Zhou,et al.  BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice , 2017, Proceedings of the National Academy of Sciences.

[12]  M. Abdelrahim,et al.  Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam , 2017, International journal of cancer.

[13]  P. Filippakopoulos,et al.  Functions of bromodomain-containing proteins and their roles in homeostasis and cancer , 2017, Nature Reviews Molecular Cell Biology.

[14]  María Jesús Fernández-Ávila,et al.  A genome-wide screening uncovers the role of CCAR2 as an antagonist of DNA end resection , 2016, Nature Communications.

[15]  H. J. Kim,et al.  Positive regulation of β-catenin–PROX1 signaling axis by DBC1 in colon cancer progression , 2016, Oncogene.

[16]  A. Rashid,et al.  Development of a murine colonoscopic polypectomy model (with videos). , 2016, Gastrointestinal endoscopy.

[17]  M. Koegl,et al.  Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition , 2016, Nature chemical biology.

[18]  D. Arango,et al.  Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells , 2016, Molecular Cancer Therapeutics.

[19]  Simon J Elsässer,et al.  Genetic code expansion in stable cell lines enables encoded chromatin modification , 2016, Nature Methods.

[20]  Amanda J. Guise,et al.  The Proteomic Profile of Deleted in Breast Cancer 1 (DBC1) Interactions Points to a Multifaceted Regulation of Gene Expression* , 2015, Molecular & Cellular Proteomics.

[21]  A. Chinnaiyan,et al.  aBETting therapeutic resistance by Wnt signaling , 2015, Cell Research.

[22]  David E. Williams,et al.  Nrf2 status affects tumor growth, HDAC3 gene promoter associations, and the response to sulforaphane in the colon , 2015, Clinical Epigenetics.

[23]  Francisco J. Sánchez-Rivera,et al.  Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma , 2015, Nature Medicine.

[24]  L. Zannini,et al.  CCAR2/DBC1 is required for Chk2-dependent KAP1 phosphorylation and repair of DNA damage , 2015, Oncotarget.

[25]  S. Westerheide,et al.  DBC1/CCAR2 and CCAR1 Are Largely Disordered Proteins that Have Evolved from One Common Ancestor , 2014, BioMed research international.

[26]  Thomas Wieland,et al.  Alignment-Annotator web server: rendering and annotating sequence alignments , 2014, Nucleic Acids Res..

[27]  U. Landegren,et al.  Protein biomarker validation via proximity ligation assays. , 2014, Biochimica et biophysica acta.

[28]  Marco Biasini,et al.  SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information , 2014, Nucleic Acids Res..

[29]  Jiandong Chen,et al.  hMOF Acetylation of DBC1/CCAR2 Prevents Binding and Inhibition of SirT1 , 2013, Molecular and Cellular Biology.

[30]  David E. Williams,et al.  HDAC turnover, CtIP acetylation and dysregulated DNA damage signaling in colon cancer cells treated with sulforaphane and related dietary isothiocyanates , 2013, Epigenetics.

[31]  Hassan Ashktorab,et al.  Epigenetic inactivation of endothelin‐2 and endothelin‐3 in colon cancer , 2013, International journal of cancer.

[32]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[33]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[34]  David E. Williams,et al.  A role for low-abundance miRNAs in colon cancer: the miR-206/Krüppel-like factor 4 (KLF4) axis , 2012, Clinical Epigenetics.

[35]  C. Löhr,et al.  NADPH oxidase overexpression in human colon cancers and rat colon tumors induced by 2‐amino‐1‐methyl‐6‐phenylimidazo[4,5‐b]pyridine (PhIP) , 2011, International journal of cancer.

[36]  David E. Williams,et al.  Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly , 2011, Molecular Cancer.

[37]  E. Chini,et al.  HDAC3 Is Negatively Regulated by the Nuclear Protein DBC1* , 2010, The Journal of Biological Chemistry.

[38]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[39]  H. Fukuhara,et al.  Identification of DBC1 as a transcriptional repressor for BRCA1 , 2010, British Journal of Cancer.

[40]  G. Gores,et al.  Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. , 2010, The Journal of clinical investigation.

[41]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[42]  Junjie Chen,et al.  DBC1 is a negative regulator of SIRT1 , 2008, Nature.

[43]  K. Henrick,et al.  Inference of macromolecular assemblies from crystalline state. , 2007, Journal of molecular biology.

[44]  J. Amos-Landgraf,et al.  A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer , 2007, Proceedings of the National Academy of Sciences.

[45]  U. Landegren,et al.  Direct observation of individual endogenous protein complexes in situ by proximity ligation , 2006, Nature Methods.

[46]  Yi Zhang,et al.  Tudor, MBT and chromo domains gauge the degree of lysine methylation , 2006, EMBO reports.

[47]  P. Karplus,et al.  A Novel Mechanism of Chemoprotection by Sulforaphane , 2004, Cancer Research.

[48]  Jaime Prilusky,et al.  Automated analysis of interatomic contacts in proteins , 1999, Bioinform..

[49]  B. Bernstein,et al.  Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. , 2018, Cancer cell.

[50]  Jason J Paxman,et al.  Bioinformatics Tools and Resources for Analyzing Protein Structures. , 2017, Methods in molecular biology.

[51]  M. Bedford,et al.  Protein-domain microarrays. , 2004, Methods in molecular biology.

[52]  W. House,et al.  Detection of mycoplasma in cell cultures. , 1967, The Journal of pathology and bacteriology.